• VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update

  • VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update

  • Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring

  • VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update

  • VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update

  • VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper

  • VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary

  • VolitionRx Limited Appoints Two New Directors

  • VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update

  • New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis

  • VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update

  • VolitionRx Limited to Present at Conferences in March 2021

  • VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock

  • VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

  • VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

  • VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts

  • National Taiwan University Hospital Presents Data on Nu.Q™ Assay Performance at the World Conference on Lung Cancer

  • VolitionRx Limited Opens its New Manufacturing Facility in Belgium

  • VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus